Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women

Menopause

Volumn 10, Issue 3, 2003, Pages 241-249

  Rubinacci, Alessandro ^a   Peruzzi, Elena ^b   Modena, Alberto Bacchi ^c   Zanardi, Ettore ^d   Andrei, Bruno ^e   De Leo, Vincenzo ^f   Pansini, Francesco Saverio ^g   Quebe Fehling, Erhard ^h   De Palacios, Patricia Ibarra ^h  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Respiratory Clinical Research   (Italy)

^c MAGGIORE HOSPITAL   (Italy)

^d BELLARIA HOSPITAL   (Italy)

^e Divisione di Ginecologia Ostetricia   (Italy)

^f UNIVERSITY OF SIENA   (Italy)

^g Az OspArcispedale S A Univ S   (Italy)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bone loss; Estradiol; Estrogen replacement therapy; Postmenopausal women; Transdermal delivery

Indexed keywords

BIOCHEMICAL MARKER; ESTRADIOL PLUS NORETHISTERONE ACETATE; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; BONE DENSITY; BONE REMODELING; BONE TURNOVER; BREAST CANCER; BREAST TENDERNESS; CALCIUM INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPEPSIA; ERYTHEMA; FEMALE; FEMUR; GASTRITIS; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; LUMBAR SPINE; MULTICENTER STUDY; NORMAL HUMAN; PARALLEL DESIGN; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN IRRITATION; SPOTTING; STATISTICAL ANALYSIS; UTERUS BLEEDING;

ADMINISTRATION, CUTANEOUS; BONE DENSITY; BONE REMODELING; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; NORETHINDRONE; OSTEOPOROSIS, POSTMENOPAUSAL; PROGESTERONE CONGENERS; TREATMENT OUTCOME;

EID: 0038792302     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200310030-00012     Document Type: Article

References (52)

1. Ginsburg J, Hardiman P, Okolo S. Hormone replacement therapy in general practice. Br Med J 1991;302:1601-1602.
2. Christiansen C, Lindsay R. Estrogens, bone loss and preservation. Osteoporosis Int 1990;1:7-13.
3. Heaney RP, Recker RR, Saville PD. Menopausal changes in bone remodelling. J Lab Clin Med 1978;92:964-970.
4. Lindsay R, Hart DM, Aitken JM et al. Long-term prevention of postmenopausal osteoporosis by estrogen. Lancet 1976;1:1038-1041.
5. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of WHO study group. World Health Organ Tech Rep Ser 1994;843:1-129.
6. Mattsson LA, Bohnet HG, Gredmark T, et al. Continuous combined hormone replacement: randomised comparison of transdermal and oral preparations. Obstet Gynecol 1999;94:61-65.
7. Birkhaüser MH, Haenggi W. Benefits of different routes of administration. Int J Fertil Menopausal Stud 1994;39(Suppl 1):11-19.
8. Kanis JA. Estrogens, the menopause and osteoporosis. Bone 1996;19(Suppl):185-190.
9. Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990;336: 265-269.
10. Eriksen EF, Kassem M, Langdahl B. European and North American experience with THRT for the prevention of osteoporosis. Bone 1996;19(Suppl):179-183.
11. Gallagher JC. Estrogen: prevention and treatment of osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis, San Diego: Academic Press, 1996:1191-1208.
12. Lindsay R, Bush TL, Grady D, et al. Estrogen replacement in menopause. J Clin Endocrinol Metab 1996;81:3829-3838.
13. Lindsay R. Estrogens, bone mass and osteoporotic fracture. Am J Med 1991;91(Suppl):10-13.
14. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102: 319-324.
15. Michaelsson K, Baron J, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. Br Med J 1998;316:1858-1863.
16. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759-763.
17. Bruschi F, Meschia M, Perotti D, et al. 25 μg/day of transdermal estradiol and bone turn-over in late postmenopausal years. IV. European Congress on Menopause, 1997. Abstract FC2-8.
18. Evans SF, Davie MWJ. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clin Endocrinol 1996;44:79-84.
19. Cooper C, Stakkestad JA, Radowicki S, et al. The International Study Group. Matrix delivery of transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women. Osteoporosis Int 1999;9:358-366.
20. Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. Obstet Gynecol 1999;94:330-336.
21. Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of lowdose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized controlled trial. Ann Intern Med 1999;130:897-904.
22. Delmas PD, Confavreux E, Garnero P, et al. A combination of lowdose of 17β-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporosis Int 2000;11:177-187.
23. Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 1997;157:2609-2615.
24. Lindsay R, Gallagher JC, Kleerekoper M, Pickar J. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-2676.
25. Shapiro S, Kelly JP, Rosenberg L, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985;13:969-972.
26. Utian WH. Transdermal estradiol overall safety profile. Am J Obstet Gynecol 1987;156:1335-1338.
27. Ettinger B, Golditch IM, Friedman G. Gynecologic consequences of long-term, unopposed estrogen replacement therapy. Maturitas 1988;10:271-282.
28. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349: 458-461.
29. Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459-461.
30. Christiansen C, Riis BJ, Nilas L, et al. Uncoupling of bone formation and resorption by combined oestrogen and progestogen therapy in postmenopausal osteoporosis. Lancet 1985;2:800-801.
31. Hahn RG, Nachtigall RD, Davies TC. Compliance difficulties with progestin-supplemented oestrogen replacement therapy. J Fam Pract 1984;18:411-414.
32. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995; 86:306-316.
33. Mattsson LA, Cullberg G, Samsioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 1982;4:95-102.
34. Archer DF, Dorin MH, Heine W, et al. Uterine bleeding in post-menopausal women on continuous therapy with estradiol and norethindrone acetate. Obstet Gynecol 1999;94:323-329.
35. Johannisson E, Holinka CF, Arrenbrecht S. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium. Int J Fertil Womens Med 1997;42(Suppl 2):388-398.
36. Garnero P, Hauser E, Chapuy MC, et al. Can markers of bone turnover predict hip fractures in elderly women? EPIDOS study. 17th annual meeting of the American society for bone and mineral research, 1995; Abstract 6.
37. Eyre DR, Koop TJ, Van Ness KP. Quantitation of hydroxypyridinum crosslinks in collagen by high-performance liquid chromatography. Ann Biochem 1984;137:380-388.
38. Campodarve I, Ulrich U, Bell N, et al. Urinary N-telopeptide of type I collagen monitors bone resorption and may predict change in bone mass of the spine in response to hormone replacement therapy, 17th annual meeting of the American society for bone and mineral research, 1995; Abstract P215.
39. Bergami MR, Gasparro C, Bianchi P, Aguzzi F, Two new commercially available procedures for separation of alkaline phosphatase isoenzymes in serum evaluated. Giorn It Chim Clin 1992;17:123-127.
40. Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. Berlin, Germany: Springer-Verlag, 1994.
41. Heshmati HM, Khosla S, Robins SP, et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002;17:172-178.
42. Lindsay R, Hart DM, Purdie D, et al. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med 1978;54:193-195.
43. Riis BJ, Christiansen C, Johansen JS, Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 1990; 70:920-924.
44. Ravn P, Bidstrup M, Wasnich R, et al. Alendronate and estrogenprogestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. Ann Intern Med 1999;131:935-941.
45. Hosking D, Chilvers C, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. New Engl J Med 1998;338:485-492.
46. Ryan PJ, Harrison R, Blake GM, Fogelman I. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 1992;99:325-328.
47. Schneider HP, Gallagher JC. Moderation of the daily dose of HRT: benefits for patients. Maturitas 1999;33(Suppl):25-29.
48. Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990;75(Suppl 4):59-76, 81-83.
49. Rozenberg S, Ylikorkala, Arrenbrecht S. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. Int J Fertil Womens Med 1997;42(Suppl 2):376-387.
50. Marslew W, Riis BJ, Christiansen C. Bleeding patterns during continuous combined estrogen-progestogen therapy. Am J Obstet Gynecol 1991;164:1163-1168.
51. Gräser T, Koytchev R, Römer T, et al. Dienogest as a progestin for hormone replacement therapy. Drugs Today 1999;35(Suppl C):115-126.
52. Nand SL, Webster MA, Baber R, O'Connor V. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group. Obstet Gynecol 1998;91:678-684.